MedPath

Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes

Recruiting
Conditions
Diabetes Mellitus, Type 2
Bone Health
Bariatric Surgery
Obesity, Morbid
Interventions
Procedure: Bariatric surgery
Registration Number
NCT03455868
Lead Sponsor
CHU de Quebec-Universite Laval
Brief Summary

Background: Bone fragility is a complication of type 2 diabetes. Diabetes treatments may ameliorate or deteriorate bone fragility in this population. Bariatric surgery is gaining in popularity in people with type 2 diabetes and may impact bone health. Objectives: To evaluate the impact of the most popular bariatric procedure worldwide (sleeve gastrectomy (SG)) on vBMD by QCT in patients with type 2 diabetes; Secondary aims: (1) to identify the determinants of vBMD after bariatric surgery in patients with type 2 diabetes; (2) to compare vBMD and its potential determinants after bariatric surgery with obese controls without diabetes as well as with controls without obesity and normoglycemia.

Detailed Description

This is a multicentre, prospective and observational study comprising a bariatric group with or without diabetes undergoing SG (n=70) and one control group (n=30).

Outcome measures are assessed before and at 4 months, 8 months, one year and 3 years after surgery in the bariatric groups and at a single visit for the control group.

Bariatric groups will include adult men and women with or without type 2 diabetes and obesity undergoing sleeve gastrectomy and followed at 0, 4 months, 8 months, 1 year and 3 years after surgery, and the control group will consist of 30 overweight individuals (10 men, 10 premenopausal women, 10 menopausal women) and without diabetes or prediabetes and assessed at a single visit.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • bariatric groups: men and women; 18 to 60 years old; with a BMI >=35 kg/m2; with type 2 diabetes: use of oral hypoglycemic agents or insulin OR 2 of the following tests confirming type 2 diabetes: HbA1c >=6.5%; fasting glucose >=7.0 mM; 2-h glucose post 75g oral glucose tolerance test (OGTT) >=11.1 mM) (guidelines.diabetes.ca);) or without diabetes: HbA1c <6.5% AND fasting glucose <7.0 mM; who are awaiting bariatric surgery. Control group: BMI 25.0 to 29.9 kg/m2 (overweight group); without diabetes or prediabetes: HbA1c <6.0% AND fasting glucose <6.1 mM (Diabetes Canada criteria), with a stable weight for the last 3 months.
Exclusion Criteria
  • bariatric groups: type 1 diabetes; disease (e.g. uncontrolled thyroid disease, malabsorptive or overt inflammatory disorder, metabolic bone disease, creatinine clearance <60 ml/min) or medication (e.g. glucocorticoids, anti-epileptic drugs, osteoporosis therapy and thiazolidinediones) affecting bone metabolism; BMI>60 kg/m2; CT scan impossible to perform (e.g. patient too large for the gantry aperture); pregnant women or women who plan to become pregnant during the study or women of childbearing age who do not agree to take an appropriate contraceptive method during the study; history of oesophageal, gastric or digestive surgery; history of bariatric surgery; cancer at risk of recurrence during the study; Prosthesis that could interfere with interpretation of imaging data; Chronic severe condition or illness precluding from participation in the project.

Control group: Same criteria plus: >5% change in weight in the last 3 months; pregnancy or lactation in the last year.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Sleeve gastrectomy diabetesBariatric surgery70 Men and women with or without type 2 diabetes and obesity undergoing sleeve gastrectomy
Primary Outcome Measures
NameTimeMethod
Change in areal bone mineral density at lumbar spine, hip and radiusbefore, 1 year after and 3 years after bariatric surgery

assessed by dual-energy X-ray absorptiometry (DXA)

Change in volumetric bone mineral density (vBMD) at lumbar spine, hip, tibia and radiusbefore, 1 year after and 3 years after bariatric surgery

assessed by quantitative computed tomography (QCT)

Secondary Outcome Measures
NameTimeMethod
Change in HbA1cbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

diabetes control

Change in estradiol and estronebefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in sclerostinbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in serum advanced glycation end products (AGEs)before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in measured physical activity levelbefore, 1 year after and 3 years after bariatric surgery

by accelerometer

Change in N-terminal propeptide of type 1 procollagen (P1NP)before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

serum bone formation marker

Change in C-telopeptidebefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

serum bone resorption marker

Change in fasting glucosebefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

diabetes control

Change in fasting insulinbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in serum 25-hydroxyvitamin Dbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in insulin like growth factor (IGF)-1before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in peptide YY (PYY)before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in oxidative stress markersbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in self-reported physical activity levelbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

by questionnaire

Change in osteocalcin (total, gamma-carboxylated and and under-carboxylated)before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

serum bone formation marker

Change in parathormone (PTH)before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in adiponectinbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in leptinbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in Free fatty acids (FFA)before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in fat and lean massbefore, 1 year after and 3 years after bariatric surgery

body composition assessed by bioimpedance and by DXA

Change in muscle mass and fat content at mid-femurbefore, 1 year after and 3 years after bariatric surgery

assessed by computed tomography (CT)

Change in upper extremity muscle strengthbefore, 1 year after and 3 years after bariatric surgery

assessed by hand grip strength

Change in muscle functionbefore, 1 year after and 3 years after bariatric surgery

assessed by timed up and go test

Change in gut microbiotabefore, 1 year after and 3 years after bariatric surgery

stool sample

Change in cutaneous Advanced glycation end products (AGEs)before, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

skin autofluorescence

Change in ghrelinbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

hormones involved in bone metabolism

Change in visceral and subcutaneous adipose tissuebefore, 1 year after and 3 years after bariatric surgery

body composition assessed by computed tomography (CT)

Change in physical capacitybefore, 1 year after and 3 years after bariatric surgery

assessed by 6-minute walk test

Change in balancebefore and 1 year after bariatric surgery

assessed by Fullerton Advanced Balance (FAB) Scale

Change in sociodemographic factorsbefore, 1 year after and 3 years after bariatric surgery

questionnaire

Change in nutritionbefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

3 web-based 24-h recalls

Change in bone alkaline phosphatasebefore, 4 months after, 8 months after, 1 year after and 3 years after bariatric surgery

serum bone formation marker

Change in lower extremity muscle strengthbefore, 1 year after and 3 years after bariatric surgery

assessed by knee extensor strength

Trial Locations

Locations (3)

The Research Institute of the McGill University Health Centre

🇨🇦

Montréal, Quebec, Canada

Centre de recherche du CHU de Québec - Université Laval

🇨🇦

Quebec, Canada

Centre de recherche de l'IUCPQ

🇨🇦

Québec, Canada

© Copyright 2025. All Rights Reserved by MedPath